RCT1100 for Primary Ciliary Dyskinesia

Recruiting in Palo Alto (17 mi)

+4 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: ReCode Therapeutics

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Eligibility Criteria

This trial is for healthy adults aged 18-55 who are not able to have children. Participants should be in good health as judged by medical history, lab tests, heart checks (ECG), and physical exams. They must understand the study's procedures, agree to follow them, have a BMI between 18 and 35 kg/m2, weigh at least 50 kg, and have normal lung function (FEV1 of at least 80% predicted).

Inclusion Criteria

My BMI is between 18 and 35, and I weigh at least 50 kg.

I am a healthy adult between 18-55 years old and cannot have children.

You can forcefully exhale at least 80% of the predicted volume in one second.

See 2 more

Treatment Details

Interventions

Placebo (Other)
RCT1100 (Unknown)

Trial OverviewThe trial is testing RCT1100 for safety and how well it's tolerated in people. It's the first time this drug is being given to humans with the goal of gathering early data that will help design future studies.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: RCT1100Experimental Treatment1 Intervention

Drug: RCT1100 single dose